(TMPRSS6-1) and 3 are mostly expressed in human testis while TMPRSS6-2 and TMPRSS6-4 are the main transcripts expressed in human liver, testis and pituitary.
Furthermore, we confirm the existence and analyse the relative expression of three annotated mice Tmprss6 isoforms. Using heterologous expression in HEK293 and Hep3B cells, we show that all human TMPRSS6 isoforms reach the cell surface but only TMPRSS6-1 undergoes internalization. Moreover, truncated TMPRSS6-3 or catalytically altered TMPRSS6-4 interact with HJV and prevent its cleavage by TMPRSS6-2, suggesting their potential role as dominant negative isoforms. Taken together, our results highlight the importance of understanding the precise function of each TMPRSS6 isoforms both in human and in mouse.
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| INTRODUCTION
Human type II transmembrane serine proteases (TTSPs) are a family of enzymes that consists of 17 members sharing common structural features and are considered key players of cell surface proteolysis. 1 Many TTSPs have been associated with biological processes and pathologies, which positions them as attractive therapeutic targets for diseases, such as viral infection and cancers. [2] [3] [4] TMPRSS6 (also known as matriptase-2) was first identified from foetal liver cDNA analysis, 5 and genetic mutations were later associated with iron-refractory iron deficiency anaemia (IRIDA). 6 Since then, over 40 TMPRSS6 mutations related to IRIDA have been identified. [7] [8] [9] [10] Mechanistically, TMPRSS6 acts as a negative regulator of the HAMP gene, which codes for a circulatory hormone called hepcidin that lowers iron levels through ferroportin internalization. 11, 12 At the cell surface, TMPRSS6 cleaves haemojuvelin (HJV), a bone morphogenetic protein (BMP) coreceptor that regulates the BMP/ SMAD signalling pathway leading to HAMP expression. 13, 14 Some TMPRSS6 mutations have been shown to prevent HJV cleavage either directly by altering TMPRSS6 enzymatic activity or by preventing the protease from reaching the cell surface. 15, 16 Conceivably, because TMPRSS6 inhibition could potentially lower circulatory iron levels by elevating hepcidin levels, TMPRSS6 has become an appealing therapeutic target for diseases characterized by iron overload. 17, 18 As proof of this, genetic knockdown of TMPRSS6 in mouse models of b-thalassaemia and haemochromatosis reduces iron overload-related characteristics and symptoms. 19, 20 Velasco et al. 5 first described TMPRSS6 as an 802-amino acid (aa) protein mostly expressed in the liver, but isoforms of various lengths have been annotated in different databases with some discrepancies. In fact, it is the 802aa-form (TMPRSS6 isoform 2, according to the UniProt Consortium nomenclature 21 ) that has been most commonly used. 5, 16, [22] [23] [24] [25] However, other groups, including ours, have focussed on TMPRSS6-1 (811 aa), which is known as the "TMPRSS6
canonical isoform". 13, 15, [26] [27] [28] [29] The difference between the two isoforms is the expression of TMPRSS6-1 coding exon 1, which encodes for residues 1-9 in the N-terminal, cytoplasmic portion of the protein. 30 Figure S1 and Table S4 and for the mice primer list see Figure S2 and Table S5 .
| Plasmid construction
The cDNAs encoding TMPRSS6-1 and HJV were obtained and cloned as previously described. 26 TMPRSS6-2 construct was obtained using the QuikChange site-directed mutagenesis kit (Agilent Technologies, Santa Clara, CA). TMPRSS6-3 and TMPRSS6-4 constructs were obtained by inserting a synthetic double-stranded DNA block coding for the isoform sequence into a modified form of pcDNA6/V5-His (Invitrogen) that was previously described. 26 Additional details are provided in the supplemental data.
| Immunofluorescence
Cells were seeded on poly-L-lysine-coated coverslips. Cells were transfected with appropriate plasmids. Twenty-four hours later, cell surface TMPRSS6 was labelled for 1 hour at 4°C. Cells were washed and incubated at 37°C for 15 or 30 minutes. Cells were then prepared as previously described. 35 Cells were examined on an inverted spectral scanning confocal microscope FV1000 (Olympus, Tokyo, Japan). Additional details are provided in the supplemental data.
| Expression and detection of TMPRSS6
Cells were transfected with TMPRSS6 isoform cDNAs performed with Lipofectamine 3000 in 6-well plates. Twenty-four hours later, the cell media were replaced with HCELL-100 media for 24 hours. Cell media were collected and concentrated, and cells were lysed. Samples were loaded on 12% SDS-PAGE and analysed by immunoblotting. Additional details are provided in the supplemental data.
| Proteolytic activity measurements in the cell media
At 24 hours post-transfection, the cell media were replaced with HCELL-100 media for another 24 hours. The media were collected, and activity was measured by the release of fluorescence from Boc-QAR-AMC cleavage. 26 Additional details are provided in the supplemental data.
| Membrane isolation and proteolytic activity measurements of isolated membrane fractions
Hep3B cells were transfected with TMPRSS6 isoform cDNAs performed with Lipofectamine 3000 in 10 cm culture dishes. Membranes were then isolated using ProteoExtract Native Membrane Extraction Kit as previously described. 36 The activity in the membrane fractions was measured using Boc-QAR-AMC fluorogenic substrate in assay buffer as previously described. 37 Samples were loaded on 12% SDS-PAGE and analysed by immunoblotting.
| Statistical analysis
Statistical analyses were conducted using GraphPad Prism version 7.0c (GraphPad Software, La Jolla, CA). Outliers were removed using the ROUT method (Q = 1%). One-sample t test analysis (hypothetical mean fixed at 1) was used to compare the activity of isoforms relative to mock transfected cells (fold induction). P values <.05 were considered statistically significant ( †). Normality was assessed using the D'Agostino-Pearson omnibus normality test before using nonparametric Kruskal-Wallis test to compare the activity between the isoforms. P values <.05 were considered statistically significant (*). 
| HJV processing by TMPRSS6
Cells were cotransfected with one or two TMPRSS6 isoforms cDNA and HJV transcript variant a. At 24 hours post-transfection, cell media were replaced with HCELL-100 for another 24 hours then collected and concentrated. The cells were lysed and samples were loaded on 12% SDS-polyacrylamide gels and analysed with immunoblotting.
Additional details are provided in the supplemental data.
3 | RESULTS
| Expression of TMPRSS6 transcripts in human
The human TMPRSS6 gene is located on chromosome 22 (22q12. 3) and is expressed as 7 known different transcripts (Ensembl database), but only 4 of them have a well-supported annotation and are predicted to be expressed as proteins ( Figure 1A ). 30 These transcripts encode 4 TMPRSS6 isoforms that lead to the production of different proteins ( Figure 1B 
annotations, including one coding for a protein of 461 aa (ENST00000442782) that expresses the first 9 coding exons of TMPRSS6-1 but has an alternatively spliced form of exon 10 that drives the expression of a truncated isoform in the second CUB domain (Ensembl annotation). 30 The second annotation for TMPRSS6-3 describes a protein of 452 aa (UCSC annotation uc003aqu.3) that has the same non-coding exon 1 than TMPRSS6-2.
Finally, TMPRSS6-4 (ENST00000406856, RefSeq NM_001289000, 824 aa) also possesses the same non-coding exon 1 than TMPRSS6-2
and expresses an additional exon between exons 16-17 coding for a 22-aa insertion in the catalytic domain.
To the best of our knowledge, functional differences between (Figure 2A ). 32 We found that TMPRSS6 is mainly expressed in the liver with lower levels We next confirmed the existence of the four TMPRSS6 isoforms performed with RT-PCR analysis on human total RNA ( Figure 2C ).
We also detected TMPRSS6-2, TMPRSS6-3 and TMPRSS6-4 in two different human RNA liver samples (single donor and pool of 5 individuals) ( Figure 2D ).
Taken together, these results point to TMPRSS6-2 as being the main transcript in liver and TMPRSS6-4 as a relatively abundant while TMPRSS6-1 and 3 are expressed at more negligible levels.
Whether TMPRSS6-3 contains the same exon 1 than TMPRSS6-1 is unclear as 2 different annotations diverge on this point. Thus, to verify expression of exon 1 in TMPRSS6-3, we analysed TMPRSS6-3 expression in all 56 cell lines available in The Human Protein Atlas database ( Figure S3 ). 33 HepG2 cells expressed the highest levels of TMPRSS6-3, and we observed that elongated exon 10 is present when analysing read alignments compared to liver samples, but TMPRSS6-1 coding exon 1 is absent ( Figure S3 ). This suggests that TMPRSS6-3 is expressed as a 452 aa protein in liver-derived cells, in accordance with the UCSC annotation. We analysed the expression of these isoforms within healthy mice liver samples performed with RNA-seq data analysis. (Figure 3C) . We found that Tmprss6-1 is the main expressed isoform (79%), with Tmprss6-2 in lower abundance (21%). Tmprss6-X2 was not detected. To confirm the presence of Tmprss6 isoforms, we performed RT-PCR on mice primary hepatocytes. All transcripts were detected using this technique ( Figure 3D ). These results confirm the existence and reveal the differential expression of annotated Tmprss6 isoforms in mouse liver. Notwithstanding the fact that the mouse is an interesting and essential model to study TMPRSS6 function, mouse isoforms do differ from those found in human. However, we nonetheless focused on characterizing the human isoforms of this protease.
| Human TMPRSS6 isoforms have different functionalities
We previously showed that TMPRSS6-1 contained a cell surface internalization motif in its cytoplasmic tail (aa 2-11), 26 We next examined the catalytic-related functionalities of TMPRSS6-V5-tagged isoforms in transiently transfected Hep3B cells.
Because this cell line is derived from liver (where TMPRSS6 is mostly expressed), it may be a better model to mimic the physiological conditions of the liver. We addressed the ability of TMPRSS6 to be shed from the cell surface, which is an event dependent on TMPRSS6 catalytic activity. 24, 26 Immunoblotting shows that all isoforms are expressed in cell lysates as zymogen forms migrating at >100 kDa for TMPRSS6-1, TMPRSS6-2 and TMPRSS6-4 or at >50 kDa for the truncated TMPRSS6-3 ( Figure 5A , upper panel).
Interestingly, and unlike TMPRSS6-1 and TMPRSS6-2, TMPRSS6-4
does not undergo shedding of its catalytic domain ( Figure 5A , lower panel). These results confirm those obtained in HEK293-transfected cells ( Figure S4 ).
The catalytic activities of TMPRSS6 isoforms were then determined in the extracellular medium of Hep3B-transfected cells (Fig- ure 5B). Proteolytic activity was detected in the media of cells | 2503
with TMPRSS6-2 than with TMPRSS6-1 ( Figure S4 ). We have been suggested that the statistically significant differences in activity measured in HEK293 cells media might be caused by the internalization of TMPRSS6-1, thus allowing more relative proteolytic activity for TMPRSS6-2 as it does not undergo internalization and remains at the cell surface where it can be shed. 
| Human TMPRSS6 isoforms interact with HJV
Even though TMPRSS6-3 does not have LDLRA or catalytic domains and TMPRSS6-4 has altered catalytic activity, we examined whether these isoforms interact with HJV. 13, 29 Proteins from Hep3B cells cotransfected with TMPRSS6 isoforms and HJV were immunoprecipitated using an anti-V5 antibody, and the ability to interact with HJV was verified by immunoblotting with HJV antibodies. Interestingly, all four TMPRSS6 isoforms interacted with HJV as seen by the detected 50 kDa form ( Figure 6A ). These results indicate that neither TMPRSS6 catalytic domain, as previously suggested, 13 nor its LDLRAs domains are required for interaction with HJV.
We next assessed the ability of these isoforms to cleave HJV.
Immunoblotting of media proteins reveals that when transfected alone, HJV is shed in the media and immunoreactive proteins, ranging from 50 to 30 kDa, can be detected ( Figure 6B , lower panel).
When cotransfected with TMPRSS6-1 or TMPRSS6-2, lower molecular weight bands appear, which indicates proteolytic cleavage. 29 In contrast, TMPRSS6-3 and TMPRSS6-4 do not cleave HJV ( 
| DISCUSSION
TMPRSS6 is a type II serine protease mainly expressed at the cell surface of hepatocytes and plays an important role in iron regulation, most notably, through HJV cleavage, thus regulating the BMP/ SMAD signalling pathway, leading to hepcidin production. 13, 14 Our findings reveal the existence of 4 distinct TMPRSS6 isoforms and highlight different relative abundance in human tissues. By analysing publicly accessible RNA-seq data, we demonstrate that TMPRSS6-2 has the highest expression in human liver and should be considered the main liver isoform. We also show that TMPRSS6-1, which is considered the canonical variant according to UniProt Consortium, 21 is expressed in testis at low levels and not detected in the liver using RNA-seq and RT-PCR. Interestingly, using a combination of techniques, we show that TMPRSS6-3 (lacking LDLRA and catalytic domains) is expressed at very low levels in liver but is expressed in testis. Importantly, we report that TMPRSS6-4 is expressed in human liver which suggests that this isoform could have a significant role in hepatic functions.
We also reveal the existence of three Tmprss6 mouse isoforms and studied their expression performed with RNA-seq data analysis of mouse livers. We also confirmed the expression of these isoforms using PCR amplification on mice primary hepatocytes. The differences between mice Tmprss6 isoforms are subtle but will ultimately need to be investigated. Moreover, it is important to note that at the present time, there is less data available for mice than for humans and therefore mice annotations may not be as reliable as human annotations in databases. Thus, the possibility that other
Tmprss6 isoforms exist cannot be ruled out.
Using heterologous expression in HEK293 and Hep3B cells, we
show that all human TMPRSS6 isoforms reach the cell surface.
While TMPRSS6-1 undergoes constitutive internalization, as F I G U R E 6 TMPRSS6 isoforms interaction with haemojuvelin. (A) Hep3B cells were cotransfected with TMPRSS6V5-tagged and haemojuvelin (HJV). Immunoprecipitation was performed in cell lysate using an anti-V5 antibody. Samples were loaded on 10% SDSpolyacrylamide gels and immunoblotting was performed using anti-HJV or anti-V5 antibodies (n = 3). (B) Hep3B cells were cotransfected with TMPRSS6V5-tagged isoforms and HJV. HJV cleavage in cell media was detected by immunoblotting with anti-HJV antibody. Equal amounts of cell lysate (CL) and concentrated cell medium (CM) were loaded on 12% SDS-polyacrylamide gels. Cell lysate GAPDH was blotted as a loading control (n = 3). (C) Hep3B cells were cotransfected either with HJV alone or in combination with one or two TMPRSS6V5-tagged isoform. Equal amounts of cell lysate (CL) and concentrated cell medium (CM) were loaded on 12% SDS-polyacrylamide gels. Cell lysate GAPDH was blotted as a loading control (n = 3) previously described by our group, 26 TMPRSS6-2, TMPRSS6-3 and TMPRSS6-4 remain at the plasma membrane. We also describe the inability of TMPRSS6-4 to undergo auto-activation, which leads to the production of a catalytically altered protein unable to cleave HJV in the cell media compared to TMPRSS6-1 and TMPRSS6-2. Importantly and regardless of the presence of catalytic domains or activity, we show that TMPRSS6-3 and TMPRSS6-4 interact with HJV. This finding correlates with the results of Silvestri et al. 13 and suggests that TMPRSS6 ectodomains are involved in interactions with HJV.
Moreover, we show that TMPRSS6-3 and TMPRSS6-4 act as dominant negative regulators of HJV cleavage by TMPRSS6. We believe that, similar to the TMPRSS6 mask mutant, 13 TMPRSS6-3 and TMPRSS6-4 could represent a novel mechanism of iron regulation.
Indeed, similar to TMPRSS6-3, the catalytically truncated TMPRSS6 mask mutant interacts with HJV 13 but does not repress hepcidin promoter activation. 40 Moreover, as TMPRSS6 proteolytic activity has been previously described as protective towards prostate cancer in vitro, 41 truncated TMPRSS6-3 or functionally altered TMPRSS6-4 expression could be related to cancer development and their role in cancers should be thoroughly studied.
Therefore, transcriptional regulation of human isoforms under different conditions could be of great interest in both iron regulation and cancer-related contexts. The effect of factors known to regulate TMPRSS6 expression, such as IL-6, LPS and BMP-6, 39,42 should be taken into consideration in human hepatoma cell lines, but also in mice to see if they affect expression levels of specific TMPRSS6 isoforms.
Of note, we had previously demonstrated 26 (and validated herein) that only TMPRSS6-1 undergoes internalization when expressed in two heterologous model, one of which being primary hepatocytes. Therefore, we believed isoform 1 was expressed in the liver. Because our present results reveal that isoform 1 is not detected in liver, we believe our previous data, 26 which used high concentrations of IgG antibodies (800 nmol/L) to label cell surface TMPRSS6, might therefore be a consequence of internalization by the IgG receptor FcRn (FCGRT), known to be expressed in both hepatocytes 43 and HepG2 cells. 33 On the other hand, it is clear that residues 1-9 encoded by exon 1 are responsible for the internalization of that isoform as validated when the isoform is expressed using heterologous expression in HEK293 and Hep3B cell lines.
Taken together, our results highlight the importance of identifying which TMPRSS6 isoforms are expressed in human tissues as well as the properties these isoforms possess. Considering the important role of TMPRSS6 in iron regulation, the protease isoforms herein described and studied should be taken into account in future studies, especially for TMPRSS6-3 and TMPRSS6-4, for which physiological functions are still to be elucidated.
